Monitor progress toward FDA 510(k) clearance and validation study results—success could position INBS for high-margin entry into the growing roadside testing market. However, with a $5M market cap and no near-term revenue visibility, execution risk remains high.
Price Chart
Executive Summary
Intelligent Bio Solutions (INBS) announced a validation study aimed at reducing its drug screening system's analysis time from 10 minutes to under 3 minutes, targeting the $1.62 billion U.S. roadside testing market by 2030. The company is also pursuing FDA 510(k) clearance for opiate detection to expand beyond current forensic-only use in the U.S.
Key Facts
- INBS launched a validation study to reduce drug test analysis time from 10 minutes to under 3 minutes.
- U.S. roadside drug testing market projected to reach $1.62 billion by 2030, growing at 4.71% CAGR.
- Company is pursuing FDA 510(k) clearance for detection of codeine to expand U.S. market access.
- Current system collects samples in under a minute and provides results within 10 minutes; used in forensic settings in the U.S. and workplace testing outside the U.S.
- Forward-looking statements dominate; no financial results or commercial milestones disclosed.
Financial Impact
Potential long-term revenue expansion if FDA clearance is obtained and faster testing is validated, but no immediate financial impact due to early-stage development.
Risk Factors
- Validation study may not achieve sub-3-minute results or fail to meet regulatory standards.
- FDA clearance for broader use is uncertain and could be delayed or denied.
- Company has minimal current revenue and depends on successful commercialization of unproven speed improvements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3277120 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 10-K/A | $1.69 | awaiting T+20 | — | $1.64 (−2.67%) |
Oct 13, 2026 13d ago | 8-K | $1.45 | awaiting T+20 | — | $1.64 (+13.10%) |
Sep 24, 2026 4w ago | EFFECT | $1.71 $1.69 | ▲ +1.46% | ▲ +1.04% | $1.64 (+4.09%) |
Sep 15, 2026 5w ago | S-3 | $1.97 $1.48 | ▼ −24.87% | ▼ −28.05% | $1.64 (−16.75%) |
Sep 11, 2026 6w ago | 8-K | $2.07 $1.51 | ▼ −27.05% | ▼ −29.32% | $1.64 (−20.77%) |
Sep 9, 2026 6w ago | 8-K | $2.24 $1.59 | ▼ −29.02% | ▼ −30.96% | $1.64 (−26.79%) |
Sep 2, 2026 7w ago | 8-K | $2.30 $1.66 | ▲ +27.83% | ▲ +26.64% | $1.64 (+28.70%) |
Aug 19, 2026 9w ago | 8-K | $2.67 $2.05 | ▼ −23.22% | ▼ −21.70% | $1.64 (−38.58%) |
Aug 19, 2026 9w ago | Press Release | $2.67 $2.05 | ▲ +23.22% | ▲ +21.70% | $1.64 (+38.58%) |
Aug 17, 2026 10w ago | Press Release | $3.37 $2.05 | ▼ −39.17% | ▼ −37.19% | $1.64 (−51.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers